Background {#Sec1}
==========

Numerous studies have been designed to investigate the early mortality of patients admitted in ICU. They focus on mortality at ICU discharge, at 28 days or/and at hospital discharge \[[@CR1]--[@CR3]\]. Case fatality is high, ranging from 14 to 44 % \[[@CR1], [@CR4]--[@CR6]\] and up to 50 % in septic shock patients \[[@CR7], [@CR8]\]. Although many tools are available to assess the severity of illness and help clinicians to determine a prognosis during an ICU stay (Table [1](#Tab1){ref-type="table"}), much less is known about what happens after ICU and hospital discharge.Table 1The severity of disease classification systems (or risk scores) most frequently used to evaluate the severity of ICU patientsScorePatientsEndpointMeasureReferenceAcute Physiolosy and Chronic Health Evaluation (APACHE)All ICU patientsHospital mortalityWithin 24 h of ICU admissionKnauss WA, 1981, 1985 and 1991\[[@CR67]--[@CR69]\], Zimmerman JE 2006 \[[@CR70]\]Simplified Acute Physiology Score (SAPS)All ICU patients28-day mortalityOnce, at 24 h after ICU admissionLe Gall JR, 1993 \[[@CR50]\] and Moreno RP 2008 \[[@CR71]\]Sequential Organ Failure Assessment (SOFA)All ICU patientsICU mortalityDailyVincent JL, 1996 \[[@CR51]\]Multiple Organ Dysfunction (MOD) scoreAll ICU patientsICU and hospital mortalityDailyMarshall J, 1995 \[[@CR72]\]McCabe ClassificationInfective patientsHospital mortalityAt admissionMcCabe WR, 1962 \[[@CR52]\]Sabadell ScoreAll ICU patientsHospital mortalityAt dischargeFernandez R, 2006 \[[@CR73]\]Glasgow Coma Scale (GCS)Traumatic brain injuryQuantify level of consciousnessDailyTeasdale GM, 1974 \[[@CR53]\]Confusion Assessment method for the ICU CAM-ICU)All ICU patientsIdentify deliriumDailyEly EW, 2001 \[[@CR54]\]Injury Severity Score (ISS)Trauma patientsHospital mortalityAt admissionBaker SP, 1974Trauma ScoreTrauma patientsHospital mortalityAt admissionChampion HR, 1981Lung Injury Score (Murray Score)Lung injured patientsQuantify the severity of lung injuryDailyMurray JF, 1988

To reduce the mortality rate of ICU survivors, it is important to identify the group of patients who have a higher probability of death in the year following ICU discharge and to recognize the adjustable factors associated with mortality. Few data have been published regarding the long-term outcome of ICU patients, and most importantly, there are no recommendations for the long-term management of these patients, only experts opinion have been published \[[@CR9], [@CR10]\]. Some studies have demonstrated that mortality rates among ICU survivors are higher compared to the general population \[[@CR11]--[@CR15]\] and that ICU stay impact on patients' quality of life \[[@CR16]\]. Moreover, other studies \[[@CR14], [@CR15]\] found that this over-risk of mortality rates is sustained over time persisting after 5 or 15 years of follow-up. Three studies \[[@CR11]--[@CR13]\] reported a worse survival rate for the ICU patients than that for the age-matched control population in the first year after ICU discharge, they also observed that after 2 to 4 years, the survival curves of the two groups became parallel.

Table [2](#Tab2){ref-type="table"} describes the 15 largest studies from the last 30 years, investigating the one-year outcome of ICU patients and their associated risk factors \[[@CR11], [@CR13], [@CR15], [@CR17]--[@CR28]\]. Using these 15 studies, the pooled estimate of post-ICU one-year mortality rate was 18.8 % (95 % confidence interval: 15.1 -- 22.5 %), and the corresponding overall mortality (ICU + post-ICU one-year mortality) was 33.4 % (95 % CI: 27.0 -- 39.9 %). However, only six papers out of fifteen had a prospective and multicenter study design (most were post-hoc analyses of prospectively collected data) \[[@CR11], [@CR19], [@CR20], [@CR23]--[@CR25]\]. As expected older age was always associated with long-term mortality, along with APACHE score at admission (or within the first 24 h of the ICU stay). Other factors associated with long-term mortality were the presence and type of comorbidities and the cause of ICU admission.Table 2The 15 largest studies including consecutive ICU patients, reporting one-year outcome and published in the last 30 yearsNameCountryStudy designRecruitment periodSample sizeAge (years)Sex (M %)Severity scoreICU mortalityOne-year mortality after ICU dischargeOverall mortalityFactors associated with one-year mortalityZaren B, 1989 \[[@CR12]\]SwedenO/P/S198397853.658N/R9.6 %18.7 %26.5 %age, AC (cardiac arrest, MOF, neurological or CV disease), chronic condition (DM, CHF, cortisone medication)Dragsted L, 1989 \[[@CR13]\]DenmarkO/P/S1979-198313086050.6N/R18.3 %29.8 %42.7 %Age, gender, medical admission category, cancerRochwood K 1993 \[[@CR14]\]CanadaO/P/MN/R884N/R63.218.8 .(APACHE II)14.4 %23.5 %34.5AgeNiskanen M, 1996 \[[@CR53]\]FinlandO/P/M19871218057.262.911.7 (APACHE II)9.9 %20 %27.9 %Age, gender, emergency admission, APACHE II at admission, cancer, CV dz, RF, GI dz, cardiac arrestDouglas C, 2002 \[[@CR15]\]USAO/P/MFeb 1997 - Mar 199953865.856.3N/R47.4%^a^32.5 %64.5 %N/RKeenan SP, 2002 \[[@CR16]\]CanadaO/R/MApr 1994- Mar 19962710354.357.1N/R14.3%^a^10.9 %^b^N/RAge, comorbidity (lymphoma/leukemia, HIV, RF)Kaarlola A, 2003 \[[@CR17]\]FinlandO/P/S1995591N/RN/RN/RN/RN/R36 %N/RWright JC, 2003 \[[@CR9]\]UKO/R/SJul 1985- Jul 1992210453.6N/R14 (APACHE II)20.620.236.7 %Age, APACHE II, AC(hematological and neurological dz, septic shock)Bagshaw SM, 2006 \[[@CR18]\]CanadaO/P/MMay 1999 - May 2002569364.96224.9 (APACHE II)13.4 %12.9 %24.5 %Age, medical diagnosis at admission, APACHE II score, AKIWilliams TA 2008 \[[@CR11]\]AustraliaO/P/S1987-200222298616711 (APACHE II)10.7%^a^5.4 %15.5 %Age, comorbidity, AC, new diagnosted cancerOrwelius L, 2010 \[[@CR19]\]SwedenO/P/MAug 2000- Jun 20042586N/RN/RN/R10.2 %24 %31.4 %N/RBraun A, 2012 \[[@CR20]\]USAO/P/MNov 1997 - Apr 20095181561.758.2N/R13%^a^15.3 %26.3 %Low preadmission 25(OH)D levelMeynaar IA, 2012 \[[@CR21]\]HollandO/R/SJan 2004 -- Dec 20093477N/RN/RN/R8.2 %20.1 %26.7 %Age, APACHE II, discharge not toward homeGrander W, 2013 \[[@CR22]\]AustriaO/P/SJan 2001- Jun 20041086N/RN/RN/R9.3 %15.7 %^b^N/RHR before ICU dischargeLuangasanatip N, 2013 \[[@CR23]\]ThailandO/R/SJan 2004 - Dec 20051032157.6N/RN/R31.5 %20.7 %45.7 %AC (cerebrovascular dz, cancer)FROG ICUEuropeO/P/MFrom Apr 2011 to Dec 20132250 (expected)*ICU* intensive care unit, *O* observational, *R* retrospective, *P* prospective, *S* single-center, *M* multi-center, *N/R* not reported, *CPR* cardiopulmonary resuscitation, *AKI* acute kidney injury, *WBCC* white blood cells count, *AC* admission category, *MOF* multi organ failure, *DM* diabetes mellitus, *CHF* chronic heart failure, *dz* disease, *CV* cardiovascular, *RF* respiratory failure, *GI* gastrointestinal, *25(OH)D* 25-idrossicolecalciferolo, *HR* heart rate^a^Hospital mortality (ICU mortality was not available)^b^Mortality rate was extrapolated from a Kaplan-Meier curve

The association between some biomarker plasma levels and ICU mortality has been studied previously. Although it has been shown that troponin is frequently elevated in ICU patients (from 42.1 to 47.3 %) \[[@CR29], [@CR30]\], only 22.2--25.8 % of those patients meet the diagnostic criteria for myocardial infarction. More importantly, elevated cTn during ICU stay was associated with an increased risk of ICU and hospital mortality (OR 2.53; 95 % CI, 1.89 to 3.38) \[[@CR31]--[@CR36]\]. Natriuretic peptide (NPs) levels were also associated with patients' outcome. It has been demonstrated that brain natriuretic peptide (BNP) level can predict mortality at 6 months after hospital discharge for patients admitted with acute heart failure \[[@CR37]\]. These results have been confirmed by other investigators in heart failure patients admitted to the ICU \[[@CR38]\]. High BNP levels are also associated with 30-day mortality in septic shock patients \[[@CR39], [@CR40]\]. Similarly, biomarker of inflammation and renal function have been shown to be associated with mid- and long-term outcome \[[@CR41]--[@CR47]\].

Thus, measuring cardiovascular, inflammatory and/or renal biomarkers at ICU discharge could be useful in early recognition of high risk patients in whom potential preventive or curative strategies could improve outcomes. Furthermore measuring biomarkers at discharge may allow risk stratification of patients for whom close clinical monitoring as well as chronic life-saving treatments should be introduced. For instance, implementation of oral beta-blocker at ICU discharge has proven benefits in acute heart failure patients who were admitted to the ICU for inotropic treatment (dobutamine or levosimendan) and who received oral beta-blocker therapy at discharge \[[@CR48]\]. This has been confirmed on survival at one year after discharge in ICU patients admitted for acute respiratory failure \[[@CR49]\].

Here, we describe the design of the French and euRopean Outcome reGistry in Intensive Care Unit (FROG-ICU), the main objective of which is to assess the incidence and identify the risk factors of mortality during the year following discharge from the ICU. This identification of the risks will be based on the patients' evaluations throughout their ICU stays, using clinical and "routine" biological parameters (including creatinine, sodium, potassium, hemoglobin, etc....) as well as ICU severity score systems that are already being used to assess short-term mortality as described in Table [1](#Tab1){ref-type="table"}. In addition, the effectiveness of novel cardiovascular biomarkers, including highly sensitive troponin, natriuretic peptides, sST2 and adrenomedullin (Table [3](#Tab3){ref-type="table"}) to early assess adjustable factors associated with long term mortality will be evaluated.Table 3Cardiovascular, inflammatory and renal biomarkers of potential interest in predicting long-term mortality in critically ill patientsNameFunctionClinical interestReferencesCardio-vascular biomarkerscopeptinePeptide of stress deriving from vasopressinemarker of cardiovascular diseaseKhan SQ, 2007Proenkephalinendogenous opiod polypeptide hormonmarker of cardiovascular and cerebrovascular diseaseSeizinger BR, 1985Troponin I uspart of troponin complex, heart contractionmarker of myocyte injuryLabugger R, 2000Troponine T hspart of troponin complex, heart contractionmarker of myocyte injuryLabugger R, 2000Brian natriuretic peptide (BNP)increase of natriuresis and decrease of vasculare resistancemarker of myocyte stressDavidson NC, 1994N-terminal pro-BNP (NT-proBNP)biologically inactive segment of BNPmarker of myocyte stressMoe GW, 2007adrenomedullin (ADM)vasodilatation, induction of angiogenesis, protection against oxydative stress and hypoxic injurymarker of myocyte stressKhan SQ, 2007Soluble ST2involved in cardiac remodeling and fibrosismarker of myocyte stressShah RV, 2010galectine 3involved in inflammation, fibrosis and neoplastic transformationmarker of heart failurede Boer RA, 2009Biomarkers of infection and/or inflammationC-reactive protrine (CRP)acute-phase proteinmarker of inflammation/infectionElster SK, 1956Interleukine 6pro-inflammation and anti-inflammation cytokinemarker of inflammation/infectionCastell JV, 1990procalcitonin (PCT)precursor of calcitoninmarker of infection, mostly bacterialJones AE, 2007Renal biomarkersPlasmatic cystatin Cprotein derived by all nucleated cells, readsorbed by proximal tubular cellsmarker of decrease glomerular filtration rateRoos JF, 2007Urinary cystatin Cprotein derived by all nucleated cells, readsorbed by proximal tubular cellsmarker of renal tubular injuryRoos JF, 2007Plasmatic and urinary neutrophil gelatinase associated lipocain (NGAL)involve in innate immunitymarker of renal tubular injuryKjeldsen L 1993

Methods and Design {#Sec2}
==================

Study design {#Sec3}
------------

The French and European Outcome Registry in Intensive Care Units (FROG ICU) study is a prospective, observational, multicenter cohort study, designed to assess the incidence and to identify the risk factors of mortality during the year following discharge from the ICU. The study will be conducted in France and in Belgium in accordance with Good Clinical Practice, Declaration of Helsinki 2002, validated by the ethical committee (Comité de Protection des Personnes - Ile de France IV, IRB n°00003835. Comission d'éthique biomédicale hospitalo-facultaire de l'hôpital de Louvain, IRB n°B403201213352) and was registed on ClinicalTrials.gov (NCT01367093). The study consists of two phases (Fig. [1](#Fig1){ref-type="fig"}): initially, all patients admitted to any of the participating centers during the recruitment period will be screened for the eligibility criteria listed below; subsequently, all patients included in the study who survive to ICU discharge will be followed up for one year through a telephone call and postal questionnaires at 3, 6 and 12 months.Fig. 1FROG-ICU study schema

Participants {#Sec4}
------------

The study will involve 28 medical, surgical or mixed ICUs in 19 hospitals. The study cohort will include all consecutive patients who are admitted in ICU to any of the participating centers during the recruitment period when the following inclusion criteria are met: invasive mechanical ventilation support for at least 24 h and/or treatment with a positive inotropic agent (except dopamine) for more than 24 h. Because the ethical committee waived the need for written consent, all patients and/or next of kin will be informed and will orally consent to participate; consent was documented in the medical record by the investigator. Exclusion criteria are the following: less than 18 years old; severe head injury (initial Glasgow Coma Scale \< 8) or brain death or a persistent vegetative state; pregnancy or breastfeeding; transplantation in the past 12 months; not expected to survive or to leave the hospital; and/or no social security coverage.

Duration of the study and number of participating centers {#Sec5}
---------------------------------------------------------

The duration of participation for a patient will be a maximum of 12 months after ICU discharge. The inclusion period for any center is 32 months, and we hypothesize that the average number of patients to be recruited in each center would be 10 per month. The total study duration is 44 months.

Study objectives {#Sec6}
----------------

### Primary objective {#Sec7}

The primary purpose of this study is to assess the incidence of all-cause mortality in the year following an ICU stay and to identify the factors associated with mortality; those factors include both the clinical-biological factors and the ICU risk scores.

### Secondary objectives {#Sec8}

The secondary objectives of this study are: 1) to determine the incidence and the risk factors of cardiovascular morbidity and mortality in the year following an ICU stay; 2) to evaluate quality of life in the year following an ICU stay; 3) to assess the role of novel biomarkers in assessing long-term outcome after ICU discharge (Table [3](#Tab3){ref-type="table"}).

Data collection and biological samples {#Sec9}
--------------------------------------

For each patient included, an electronic case report form will be completed that documents relevant information about the ICU stay and the one-year follow-up period. At the time of inclusion, the following will be collected: demographics, data on past medical history, ICU admitting diagnosis, hemodynamic (non-invasive and invasive) and respiratory parameters, severity of disease classification systems (SAPS-II, SOFA, CAM-ICU, McCabe Classification and GCS) \[[@CR50]--[@CR54]\]; digital electrocardiogram (EKG), recorded with CarTouch (Cardionics S.A., Bruxelles, Belgium), a high-definition electrocardiograph provided with TeleTouch software for the automatic transfer of the EKG to the informatics system. Routine laboratory tests will be performed. In 9 ICUs, an echocardiogram will also be performed within a few hours of inclusion. During the first 3 days of each ICU stay, respiratory and cardiovascular parameters (including hemodynamic and EKG) will be recorded daily and subsequently twice a week; SOFA score will be performed the first 3 days after inclusion, and routine biomarkers will be measured according to physician practice. Renal replacement therapy, death and cause of death in ICU will be collected.

The following data will be collected at ICU discharge: clinical parameters, digital EKG and routine biological assessment, ICU length of stay, duration of mechanical ventilation, SOFA score, treatment and results of echocardiogram at discharge when performed.

All patients included in the study population who survive to ICU discharge will be followed up for one additional year or until death, except for severely disabled subjects (Glasgow Outcome Scale \< 4 at discharge). One-year outcome will be evaluated through data collection at 3, 6 and 12 months after ICU discharge. At those time points, patients will be contacted by telephone, and information about vital status (patient dead or alive), re-hospitalization, and cardiovascular morbidity will be recorded. For patients lost of follow-up, the vital status will eventually be checked through the national health services records when available. In addition, 4 follow-up questionnaires will be submitted to the study population: the Hospitalization Anxiety and Depression Scale (HADS) \[[@CR55]\] and the Short Form-36 (SF-36) \[[@CR56], [@CR57]\] at discharge and at 3, 6, and 12 months after and the Impact of Event Scale-Revised (IES-R) \[[@CR58]\] at 3, 6 and 12 months; a social questionnaire for assessing patients' social environments (actual occupation, resumption of activity, level of income, marital status,...) will be submitted at 3 months after discharge.

A biological collection will be created with blood (3x10 ml in EDTA and aprotinin) and urine (10 ml) samples collected at two different time points: admission and discharge. The biological collection will allow for the measurement of novel biomarkers in a central laboratory. Table [3](#Tab3){ref-type="table"} lists the biomarkers with potential interest for the risk stratification of patient who survive an ICU stay.

Statistical analysis {#Sec10}
--------------------

Primary analysis will be performed on all patients included in the cohort. Only patients who withdrew consent will be excluded. Patients who decided to stop tracking or who were lost to follow-up will be included in the analysis. Any missing value will be replaced by the previous value (the last value carried forward method). Sensitivity analyses for missing values will be conducted, for example, using a multiple imputation (MICE, multiple imputation by chained equations \[[@CR59]\]. All tests will be bilateral formulation, with a risk of type I error of 5 %.

Calculating the number of subjects required is based on the primary endpoint, i.e., the impact and the risk factors on one year all-cause mortality. The study of the literature and the completion of the preliminary inquiry (conducted in December 2009) in 14 centers that participated to the study conduct us to assume a 1-year mortality after ICU discharge of 18 %. To ensure detection with a power of 80 % of binary prognostic factors with a prevalence of 33 % and an expected OR of 1.5 and a probability of death of approximately 18 %, 1636 patients should be included in this study \[[@CR60]\]. Assuming a rate of refusal and/or follow-up losses of 10 %, the number of patients to be included in the one-year follow-up amounts to 1800. The expected in-ICU mortality rate is 25 %. Thus, taking into account these results, the number of patients to be included is 2250.

The primary analysis will be based on the research of the determinants of 1-year mortality of patients included in the FROG-ICU (i.e., ICU patients who needed mechanical ventilation for more than 24 h and/or treatment with a positive inotropic agent over 24 and who were discharged alive from the ICU) among clinical and biological variables and biomarkers of common interest (i.e., troponins, natriuretic peptides). The regression model used will be the logistic model. The log-linearity of the quantitative variables will be systematically evaluated, and, if appropriate, variable transformations will be performed. A selection model process will be performed using stepwise selection method. The selection process model will be further validated by bootstrap \[[@CR61]\]. The existence of any collinearities will be observed, and a test of goodness of fit will be performed using the test and the van Cessie Houwelingen method \[[@CR62]\]. Finally a cross-validation procedure will be performed. The measures of association will be provided, with odds ratios and confidence intervals at 95 %. An estimate of related risks will also be conducted. Finally, the overall incidence of 1-year mortality will be estimated at a confidence interval of 95 %.

As it is now recognized that highlighting the statistically significant association between new biomarkers and patient outcomes is not sufficient to demonstrate the interest of these biomarkers in terms of risk prediction \[[@CR63]--[@CR65]\]. We will use the proposed methodology of Pencina et al., which has been used in multiple articles of application. For each biomarker of interest, the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) will be calculated, and comparisons between different biomarkers will be performed \[[@CR64]\].

Regarding quality of life, a strategy similar to that outlined for the 1-year mortality analysis will be used to assess its impact and to highlight the predictors of impaired QoL at 6 months or 1 year. QoL will be estimated using the SF-36 score (ranging from 0 to 100) \[[@CR66]\]. Altered QoL is considered when SF-36 is lower than 50. In addition, the value of the SF-36 measured in the FROG ICU study will be compared with the values that are typically found in healthy populations of the same age and sex. Interaction between quality of life and social life will be assessed by using information from the social questionnaire.

Last, regarding stress and anxiety, as previously described, IES-R higher than 30 will define post-traumatic stress disorder \[[@CR58]\] and HADS higher than 8 will defined anxiety \[[@CR55]\]. Similarly, analyses will consist in seeking to identify risk factors of stress and anxiety after ICU discharge.

Discussion {#Sec11}
==========

Very limited information is currently available concerning the risk factors for long-term survival after a stay in the ICU. Some studies have investigated the long-term prognosis of ICU patients \[[@CR11], [@CR13], [@CR15], [@CR17]--[@CR28]\], but only a few of them have been properly designed to achieve this result, in a prospective, multicenter manner and using a large number of patients \[[@CR11], [@CR19], [@CR20], [@CR23]--[@CR25]\]. Few studies have evaluated biological parameters \[[@CR25]--[@CR27]\] as factors associated with long-term mortality, and only one study has correlated the patient's condition at discharge with the long-term risk of death \[[@CR27]\]. Consequently, at the moment, there are neither guidelines nor recommendations to assist clinicians in providing optimal patient management after ICU.

Accordingly, FROG-ICU is an innovative study that reflects the endeavor of many ICU physicians to assess the incidence of all-cause mortality in the year after ICU discharge and to identify the factors associated with this mortality. The strengths of the present study are listed in Table [4](#Tab4){ref-type="table"}: first is the study design because FROG-ICU is a large observational, prospective and multicenter cohort study; second, the evaluation of each patient is performed through a comprehensive clinical assessment, instrumental tests (electrocardiogram, echocardiogram) and biological parameters; finally, all of the data are collected at admission, during the stay and at discharge.Table 4Strengths of the present studyStrengths of FROG-ICU studyStudy designObservational, non-interventional, prospective and multicenter cohort studyMethods for the evaluation of the patientComplete clinical assessment, instrumental tests (electrocardiogram, echocardiogram), biological parameters and routine biomarkers during ICU stayConstitution of a biobankFor each patient, plasma and urine will be collected. For ICU-survivor, urine and plasma at discharge will also be collectedRepeated evaluations of the patientAt admission, during the ICU stay, at discharge and during one year

Preliminary studies suggest that pre-discharge therapy, especially the oral administration of beta-blockers, may improve the survival after an ICU stay \[[@CR48], [@CR49]\]. This would be confirm or not using the FROG-ICU data notably by using causal inference approaches. Moreover all of these findings favor developing a clinical trial with inclusion criteria and number of patients to be recruited based on the present study, with the main purpose of decreasing long-term all-cause and particularly cardiovascular morbidity and mortality after ICU discharge.

To sum up, FROG-ICU has been designed to better understand long term outcome after ICU discharge as well as risk factors for all-cause and cardiovascular morbidity and associated mortality. Because it is a large prospective multicenter study that collects clinical, biological and focused cardiovascular biomarkers, FROG ICU will allow to perform a risk stratification of ICU survivors as to recognize the subset of patients who may benefit from an early intervention to allow decreased cardiovascular morbidity and related mortality. Should the cardiovascular risks be identified here and validated in a sub-cohort, a randomized controlled trial using the results of this risk stratification will be in order to demonstrate survival benefits from a pre- and post-discharge multifaceted intervention that will include close cardiovascular monitoring and oral cardio-vascular therapies.
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